For instance, in a phase I, open-label, non-randomized clinical trial, Giorgio et al. utilized the CRISPR/Cas9 system to delete the expression of TRAC and CD52 in CD19-CART cells and treat six pediatric patients with relapsed/refractory CD19-positive B-ALL. Here, CD52 is linked to acute lymphoblastic leukemia.